Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pulsing drug doses may outsmart brain metastases in lung cancer

NCT ID NCT07348965

Recruiting now Disease control Sponsor: Guangzhou University of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 26, 2026 · Updated 21 times

Summary

This study tests whether taking a higher dose of the targeted drug furmonertinib every other day can better control lung cancer that has spread to the lining of the brain (leptomeningeal metastasis). About 42 adults with a specific EGFR gene mutation will choose either the high-dose every-other-day regimen or the standard daily dose. The goal is to see if the pulsing dose improves disease control, safety, and drug levels in the spinal fluid.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial Hospital of Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, 510120, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EGFR ACTIVATING MUTATION EGFR ACTIVATING MUTATION FURMONERTINIB LEPTOMENINGEAL METASTASIS NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)